The threat, development, spread, and intensification of antimalarial drug resistance are posing tremendous challenges to malaria-control activities throughout the world.
Fundamental aspects of these activities are the identification and promotion of safe and effective therapy for acute malarial illness.
A major tool in providing guidance on appropriate therapy is the national malaria-therapy policy, which describes antimalarial drugs available for use in a given country, their relative efficacy, and how best to use them in a variety of settings, from the community to the referral hospital.
This review describes some of the factors that need to be considered in the development of a national, antimalarial drug policy as well as those that have impeded timely development of national policies, especially in sub-Saharan Africa.
Mots-clés Pascal : Paludisme, Protozoose, Parasitose, Infection, Traitement, Politique sanitaire, Résistance traitement, Monde, Homme, Plasmodium falciparum, Apicomplexa, Protozoa, Chloroquine, Chimiothérapie, Répartition géographique, Antiparasitaire, Antipaludique
Mots-clés Pascal anglais : Malaria, Protozoal disease, Parasitosis, Infection, Treatment, Health policy, Negative therapeutic reaction, World, Human, Plasmodium falciparum, Apicomplexa, Protozoa, Chloroquine, Chemotherapy, Geographic distribution, Parasiticid, Antimalarial
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0244445
Code Inist : 002B02S06. Création : 16/11/1999.